157 related articles for article (PubMed ID: 32988886)
1. FGF Expression in HPV16-positive and -negative SCC After Treatment With Small-molecule Tyrosine Kinase Inhibitors and Everolimus.
Huber L; Birk R; Knuettel M; Rotter N; Aderhold C; Scherl C; Lammert A; Jungbauer F; Kramer B
Anticancer Res; 2020 Oct; 40(10):5621-5630. PubMed ID: 32988886
[TBL] [Abstract][Full Text] [Related]
2. Tyrosine Kinase Inhibitors and Everolimus Reduce IGF1R Expression in HPV16-positive and -negative Squamous Cell Carcinoma.
Kramer B; Schell A; Aderhold C; Huber L; Mueller CE; Rotter N; Birk R
Anticancer Res; 2020 Jul; 40(7):3847-3855. PubMed ID: 32620624
[TBL] [Abstract][Full Text] [Related]
3. Targeted Treatment of HPV16-positive and -negative SCC Cells With Small Molecule Tyrosine Kinase Inhibitors and Everolimus Affects MMP2 and MMP14 Expression.
Huber L; Birk R; Knuettel M; Rotter N; Aderhold C; Scherl C; Lammert A; Jungbauer F; Kramer B
Anticancer Res; 2022 Jul; 42(7):3403-3411. PubMed ID: 35790279
[TBL] [Abstract][Full Text] [Related]
4. Apoptosis-related Proteins Are Altered by Selective Tyrosine Kinase Inhibitors and Everolimus in HPV-dependent SCC.
Birk R; Schell A; Aderhold C; Hoch S; Huber L; Mueller CE; Lammert A; Scherl C; Rotter N; Sommer JU; Kramer B
Anticancer Res; 2020 Nov; 40(11):6195-6203. PubMed ID: 33109556
[TBL] [Abstract][Full Text] [Related]
5. Targeting mTOR and AREG with everolimus, sunitinib and sorafenib in HPV-positive and -negative SCC.
Aderhold C; Faber A; Umbreit C; Birk R; Weiss C; Sommer JU; Hörmann K; Schultz JD
Anticancer Res; 2015 Apr; 35(4):1951-9. PubMed ID: 25862847
[TBL] [Abstract][Full Text] [Related]
6. Effect of Small-molecule Tyrosine Kinase Inhibitors on PDGF-AA/BB and PDGFRα/β Expression in SCC According to HPV16 Status.
Huber L; Birk R; Rotter N; Aderhold C; Lammert A; Jungbauer F; Kramer B
Anticancer Res; 2020 Feb; 40(2):825-835. PubMed ID: 32014925
[TBL] [Abstract][Full Text] [Related]
7. Impact of Small Molecules on β-Catenin and E-Cadherin Expression in HPV16-positive and -negative Squamous Cell Carcinomas.
Kramer B; Hock C; Schultz JD; Lammert A; Kuhlin B; Birk R; Hörmann K; Aderhold C
Anticancer Res; 2017 Jun; 37(6):2845-2852. PubMed ID: 28551620
[TBL] [Abstract][Full Text] [Related]
8. Small molecules alter VEGFR and PTEN expression in HPV-positive and -negative SCC: new hope for targeted-therapy.
Aderhold C; Faber A; Umbreit C; Chakraborty A; Bockmayer A; Birk R; Sommer JU; Hörmann K; Schultz JD
Anticancer Res; 2015 Mar; 35(3):1389-99. PubMed ID: 25750290
[TBL] [Abstract][Full Text] [Related]
9. Targeted Therapies in HPV-positive and -negative HNSCC - Alteration of EGFR and VEGFR-2 Expression In Vitro.
Kramer B; Hock C; Birk R; Sauter A; Stuck BA; Hörmann K; Schultz JD; Aderhold C
Anticancer Res; 2016 Jun; 36(6):2799-807. PubMed ID: 27272791
[TBL] [Abstract][Full Text] [Related]
10. HIF-1α and mTOR - Possible Novel Strategies of Targeted Therapies in p16-positive and -negative HNSCC.
Kramer B; Polit M; Birk R; Rotter N; Aderhold C
Cancer Genomics Proteomics; 2018; 15(3):175-184. PubMed ID: 29695399
[TBL] [Abstract][Full Text] [Related]
11. Small molecule-based chemotherapeutic approach in p16-positive and -negative HNSCC in vitro.
Aderhold C; Faber A; Grobschmidt GM; Chakraborty A; Bockmayer A; Umbreit C; Birk R; Stern-Straeter J; Hörmann K; Schultz JD
Anticancer Res; 2013 Dec; 33(12):5385-93. PubMed ID: 24324073
[TBL] [Abstract][Full Text] [Related]
12. Tyrosine Kinase Inhibition in HPV-related Squamous Cell Carcinoma Reveals Beneficial Expression of cKIT and Src.
Kramer B; Kneissle M; Birk R; Rotter N; Aderhold C
Anticancer Res; 2018 May; 38(5):2723-2731. PubMed ID: 29715092
[TBL] [Abstract][Full Text] [Related]
13. Co-targeting EGFR and IKKβ/NF-κB signalling pathways in head and neck squamous cell carcinoma: a potential novel therapy for head and neck squamous cell cancer.
Li Z; Liao J; Yang Z; Choi EY; Lapidus RG; Liu X; Cullen KJ; Dan H
Br J Cancer; 2019 Feb; 120(3):306-316. PubMed ID: 30585254
[TBL] [Abstract][Full Text] [Related]
14. Fibroblast growth factor (FGF), FGF receptor (FGFR), and cyclin D1 (CCND1) DNA methylation in head and neck squamous cell carcinomas is associated with transcriptional activity, gene amplification, human papillomavirus (HPV) status, and sensitivity to tyrosine kinase inhibitors.
Bao Y; Gabrielpillai J; Dietrich J; Zarbl R; Strieth S; Schröck F; Dietrich D
Clin Epigenetics; 2021 Dec; 13(1):228. PubMed ID: 34933671
[TBL] [Abstract][Full Text] [Related]
15. Effect of selective small molecule inhibitors on MMP-9 and VEGFR-1 expression in p16-positive and -negative squamous cell carcinoma.
Kramer B; Schultz JD; Hock C; Sauter A; Stuck BA; Hörmann K; Birk R; Aderhold C
Oncol Lett; 2017 May; 13(5):3269-3276. PubMed ID: 28521433
[TBL] [Abstract][Full Text] [Related]
16. Expression Patterns of CD44 and AREG Under Treatment With Selective Tyrosine Kinase Inhibitors in HPV
Kansy B; Aderhold C; Huber L; Ludwig S; Birk R; Lammert A; Lang S; Rotter N; Kramer B
Cancer Genomics Proteomics; 2020; 17(5):579-585. PubMed ID: 32859636
[TBL] [Abstract][Full Text] [Related]
17. Synergistic antitumour activity of HDAC inhibitor SAHA and EGFR inhibitor gefitinib in head and neck cancer: a key role for ΔNp63α.
Citro S; Bellini A; Miccolo C; Ghiani L; Carey TE; Chiocca S
Br J Cancer; 2019 Mar; 120(6):658-667. PubMed ID: 30765872
[TBL] [Abstract][Full Text] [Related]
18. Comparative Gene Expression Profiling of Tobacco-Associated HPV-Positive versus Negative Oral Squamous Carcinoma Cell Lines.
Lepore S; Lettini G; Condelli V; Sisinni L; Piscazzi A; Simeon V; Zoppoli P; Pedicillo MC; Natalicchio MI; Pietrafesa M; Landriscina M
Int J Med Sci; 2020; 17(1):112-124. PubMed ID: 31929745
[No Abstract] [Full Text] [Related]
19. Human papillomavirus insertions identify the PIM family of serine/threonine kinases as targetable driver genes in head and neck squamous cell carcinoma.
Broutian TR; Jiang B; Li J; Akagi K; Gui S; Zhou Z; Xiao W; Symer DE; Gillison ML
Cancer Lett; 2020 Apr; 476():23-33. PubMed ID: 31958486
[TBL] [Abstract][Full Text] [Related]
20. ERK-TSC2 signalling in constitutively-active HRAS mutant HNSCC cells promotes resistance to PI3K inhibition.
Ruicci KM; Pinto N; Khan MI; Yoo J; Fung K; MacNeil D; Mymryk JS; Barrett JW; Nichols AC
Oral Oncol; 2018 Sep; 84():95-103. PubMed ID: 30115483
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
